- Home
- LUCD vs SGMO Comparison
LUCD vs SGMO Comparison
Compare LUCD & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | SGMO |
|---|---|---|
| Founded | 2018 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.9M | 141.2M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | LUCD | SGMO |
|---|---|---|
| Price | $1.48 | $0.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $3.94 | ★ $5.75 |
| AVG Volume (30 Days) | 782.2K | ★ 8.1M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.67 | ★ 66.89 |
| EPS | N/A | ★ N/A |
| Revenue | $4,346,000.00 | ★ $36,567,000.00 |
| Revenue This Year | $7.69 | $4.79 |
| Revenue Next Year | $155.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 79.00 | ★ 88.60 |
| 52 Week Low | $0.95 | $0.35 |
| 52 Week High | $1.80 | $1.06 |
Technical Indicators
Market Signals| Indicator | LUCD | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 68.19 | 55.11 |
| Support Level | $1.01 | $0.43 |
| Resistance Level | $1.53 | $0.48 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 88.57 | 46.41 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.